KY 063

Drug Profile

KY 063

Latest Information Update: 06 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kyoto Pharmaceutical Industries
  • Class Antiplatelets; Imidazoles; Small molecules; Thrombolytics
  • Mechanism of Action Free radical scavengers; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Myocardial ischaemia

Most Recent Events

  • 06 Mar 2008 Discontinued - Preclinical for Asthma in Japan (unspecified route)
  • 06 Mar 2008 Discontinued - Preclinical for Myocardial ischaemia in Japan (unspecified route)
  • 06 Jun 2001 No-Development-Reported for Asthma in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top